SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

SGX945

SNGX·Soligenix, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 2
Time to market
At least 3-5 years away, assuming a successful Phase 2b/3 program is initiated and completed. The company has not announced a registrational trial start date and may need a partner to fund it.
Why 4/10
No hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled in the next ~12 months. SGX945 is a mid-stage (Phase 2) asset with a completed 8-patient Phase 2a study. The next catalyst would likely be initiation of a larger Phase 2b/3 trial or a partnership announcement, neither of which has a confirmed date. The company is also evaluating strategic alternatives, which could produce news but is not a dated binary event.
Actionable Insight NEUTRAL

Watch for any announcement from Soligenix regarding the next development steps for SGX945, including potential Phase 3 trial plans or a partnership/licensing deal. The company is actively evaluating strategic alternatives, so any M&A or partnership news could be a major catalyst. Also monitor for any new clinical trial initiations or regulatory milestone updates.

Price Chart

Loading chart...

Executive Summary

SGX945 (dusquetide) is Soligenix's mid-stage investigational therapy for Behçet's Disease, a rare inflammatory disorder causing painful oral and genital ulcers. It uses a novel Innate Defense Regulator mechanism that modulates inflammation without suppressing the immune system. In a small 8-patient open-label Phase 2a study, 7 of 8 patients achieved complete resolution of oral ulcers with no treatment-related adverse events, comparing favorably to the approved competitor Otezla (apremilast). The drug has accumulated multiple regulatory designations (FDA Fast Track, US and EU Orphan Drug, UK PIM). However, Soligenix is a micro-cap company (market cap roughly $7.6M) with limited cash ($9.0M), a terminated Phase 3 program for another asset (HyBryte), and no confirmed timeline for the next pivotal trial. The company is evaluating strategic alternatives including partnerships and M&A.

How It Works

SGX945 (dusquetide) is a synthetic peptide that acts as an Innate Defense Regulator (IDR). Instead of suppressing the immune system like many anti-inflammatory drugs, it modulates the body's innate immune response to reduce harmful inflammation while preserving the ability to fight infections. It targets a specific cellular pathway (the P2X7 receptor) to dampen excessive inflammatory signaling without causing broad immunosuppression.

Trial Status

A Phase 2a proof-of-concept study (8 patients, open-label) was completed in mid-2025, with positive results published in Rheumatology (Oxford) in December 2025. A Phase 2 clinical trial (DUS-AUBD-01) was initiated in November 2024. The company has not announced whether a Phase 3 registrational trial has been designed or initiated.

The Two-Sided Case

▲ Bull Case6
SGX945 (dusquetide) achieved 7 of 8 patients with complete response of oral ulcers in a Phase 2a proof-of-concept study, with no treatment-related adverse events, comparing favorably to Otezla's side effect profile (diarrhea 41%, nausea 19%, headache 14%).
The drug has received multiple regulatory designations: FDA Fast Track (Jan 2024), FDA Orphan Drug (Aug 2025), EMA positive opinion and EU Orphan Drug (Feb-Mar 2026), and UK MHRA Promising Innovative Medicine designation (Mar 2026), indicating regulatory support.
SGX945 uses a novel innate defense regulator (IDR) mechanism that modulates the immune system rather than suppressing it, potentially offering a differentiated safety profile versus existing treatments.
Behçet's disease is a rare orphan indication with unmet medical need, and orphan drug status provides 7 years (US) and 10 years (EU) of market exclusivity upon approval.
The company has cash runway into Q2 2028, providing a buffer to advance the program or complete a strategic transaction.
Analyst consensus shows 6 Buy/Strong Buy ratings vs 1 Hold, with a mean price target of $1.375 (roughly 4x the current stock price), though coverage is stale.
▼ Bear Case6
Soligenix has a market cap of roughly $7.6M and only $9.0M in cash (as of September 30, 2026), limiting its ability to fund a large Phase 3 trial without significant dilution or a partnership.
The Phase 3 FLASH2 trial for HyBryte (the company's other lead asset) was terminated in 2026 after disappointing interim results, raising questions about Soligenix's clinical development capabilities.
The company has conducted multiple ATM equity offerings in 2026, causing substantial shareholder dilution. The stock trades around $0.335, near its 52-week low of $0.28.
SGX945 has only been tested in an 8-patient open-label Phase 2a study. Larger, randomized, placebo-controlled trials are needed to confirm efficacy and safety.
Analyst coverage is stale (last action July 2025), and the company faces Nasdaq minimum bid price compliance risk.
Apremilast (Otezla, Amgen) is already FDA-approved for oral ulcers in Behçet's disease and represents established competition.

Upcoming Catalysts

  • Potential announcement of Phase 3 trial design or initiation
  • Possible partnership, licensing, or M&A transaction as part of strategic alternatives review
  • Any additional regulatory milestone or designation updates
  • Potential Nasdaq compliance update given low stock price

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Soligenix, Inc. PRESS-RELEASE SNGX ·Originating report

Sources · 8

Hover a chip for the title
1 prnewswire.com2 nasdaq.com3 prnewswire.com4 prnewswire.com5 nasdaq.com6 koin.com7 aol.com8 nasdaq.com